ENDRA Life Sciences Q3 cash burn declines on cost optimization

ENDRA Life Sciences

17/11/2025 13:10

Overview

ENDRA Q3 2025 cash burn decreased 30% to $1.2 mln due to cost optimization

Company completed $4.9 mln private placement, regaining Nasdaq compliance

Operating expenses for Q3 2025 were $1.4 mln, down from $1.5 mln in 2024

Outlook

Strategic initiative launched to enhance financial sustainability

Result Drivers

COST OPTIMIZATION - Q3 cash burn decreased 30% due to streamlined staffing and reduced overhead

PIPE FINANCING - $4.9 mln private placement completed, aiding Nasdaq compliance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Operating Expenses
$1.40 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $38.00, about 82.4% above its November 14 closing price of $6.70

Press Release: ID:nBw3cnJgTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)